GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also …
Biotechnology
JP, Tokyo [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 153.21 | 145.37 | -57.41 | |
| Graham Fair Price | -51.02 | 674.84 | 1377.69 | |
| PEG | 5452.71 | -0.35 | < 0.005 | |
| Price/Book | 8.69 | 4.42 | 4.06 | |
| Price/Cash Flow | 201.78 | -234.72 | 77.78 | |
| Prices/Earnings | 349.77 | 26.26 | 5.84 | |
| Price/Sales | 2.15 | 25.69 | 25.15 | |
| Price/FCF | 201.78 | -234.72 | 77.78 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 2.17 | 0.80 | 0.78 | |
| Operating Margin | -69.42 | 0.13 | -0.41 | |
| ROA | -76.48 | 0.02 | 0.09 | |
| ROE | 0.17 | 0.04 | -75.83 | |
| ROIC | -0.05 | 0.01 | -70.25 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.69 | 1.36 | -49.45 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -2.71 | 1.33 | -50.78 | |
| EPS QOQ | 9.37 | -0.76 | -91.90 | |
| FCF QOQ | -0.38 | -1.37 | -257.37 | |
| Revenue QOQ | -0.15 | 0.09 | -41.96 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 173.36 | 184.62 | 6.50 | |
| Days Sales Outstanding (DSO) | 65.46 | 67.93 | 3.77 | |
| Inventory Turnover | 0.52 | 0.49 | -6.10 | |
| Debt/Capitalization | 0.10 | 0.15 | 58.34 | |
| Quick Ratio | 3.48 | 2.60 | -25.22 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 696.24 | 693.76 | -0.36 | |
| Cash | 476.95 | 471.83 | -1.07 | |
| Capex | -7.01 | -6.03 | 13.96 | |
| Free Cash Flow | 36.38 | -13.06 | -64.11 | |
| Revenue | 112.54 | 119.32 | 6.02 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad